LOW IMMUNOGENICITY OF EMICIZUMAB IN PERSONS WITH HAEMOPHILIA A

被引：0
|
作者：
Schmitt, C. [1 ]
Emrich, T. [2 ]
Asikanius, E. [1 ]
Chebon, S. [1 ]
Fernandez, E. [1 ]
Petry, C. [1 ]
Yoneyama, K. [3 ]
Kiialainen, A. [1 ]
Kuebler, P. [4 ]
Niggli, M. [1 ]
Paz-Priel, I. [4 ]
Chang, T. [4 ]
机构：
[1] F Hoffmann La Roche Ltd, Basel, Switzerland
[2] Roche Diagnost GmbH, Penzberg, Germany
[3] Chugai Pharmaceut Co Ltd, Tokyo, Japan
[4] Genentech Inc, San Francisco, CA 94080 USA
来源：
HAEMOPHILIA | 2021年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
ABS141
引用
收藏
页码：96 / 97
页数：2
相关论文
共 50 条
  • [1] Low immunogenicity of emicizumab in persons with haemophilia A
    Schmitt, Christophe
    Emrich, Thomas
    Chebon, Sammy
    Fernandez, Elena
    Petry, Claire
    Yoneyama, Koichiro
    Kiialainen, Anna
    Howard, Monet
    Niggli, Markus
    Paz-Priel, Ido
    Chang, Tiffany
    [J]. HAEMOPHILIA, 2021, 27 (06) : 984 - 992
  • [2] Impact of Emicizumab on annualized bleeding rates in persons with haemophilia A in Western Kenya
    Kilach, Carole
    Greist, Anne
    Muigai, Festus Njuguna
    Njuguna, Cyrus
    Midiwo, Nancy
    Oburah, Elvis Moses
    Aliwa, Everlyne
    Korir, Racheal
    Bor, Consolata
    [J]. HAEMOPHILIA, 2022, 28 : 71 - 71
  • [3] Emicizumab: A Review in Haemophilia A
    Blair, Hannah A.
    [J]. DRUGS, 2019, 79 (15) : 1697 - 1707
  • [4] Emicizumab: A Review in Haemophilia A
    Hannah A. Blair
    [J]. Drugs, 2019, 79 : 1697 - 1707
  • [5] Bone and joint health markers in persons with haemophilia A (PwHA) treated with emicizumab in HAVEN 3
    Kiialainen, A.
    Niggli, M.
    Kempton, C.
    Castaman, G.
    Chang, T.
    Paz-Priel, I.
    Adamkewicz, J.
    Levy, G.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 : 151 - 152
  • [6] Outcomes of emicizumab-KXWH use in persons with haemophilia A at moi teaching and referral hospital
    Oburah, M. E.
    Njuguna, F.
    Greist, A.
    Kilach, C.
    Ramani, R.
    Ndemo, K.
    Njuguna, C.
    Aliwa, E.
    [J]. HAEMOPHILIA, 2024, 30 : 80 - 80
  • [7] Pharmacokinetics and biomarkers in persons with haemophilia a (PwHA) receiving emicizumab every 2 or 4 weeks
    Kiialainen, A.
    Schmitt, C.
    Adamkewicz, J. I.
    Petry, C.
    Pipe, S.
    Young, G.
    Mahlangu, J.
    Lehle, M.
    Chang, T.
    Dhalluin, C.
    Jimenez-Yuste, V.
    Meeks, S.
    Oldenburg, J.
    Shima, M.
    Chebon, S.
    Niggli, M.
    Negrier, C.
    Levy, G. G.
    [J]. HAEMOPHILIA, 2019, 25 : 45 - 46
  • [8] Emicizumab for infants and children with haemophilia A
    Levy-Mendelovich, Sarina
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2020, 191 (02) : 145 - 146
  • [9] Emicizumab for the treatment of haemophilia A: a narrative review
    Franchini, Massimo
    Marano, Giuseppe
    Pati, Ilaria
    Candura, Fabio
    Profili, Samantha
    Veropalumbo, Eva
    Masiello, Francesca
    Catalano, Liviana
    Piccinini, Vanessa
    Vaglio, Stefania
    Pupella, Simonetta
    Liumbruno, Giancarlo M.
    [J]. BLOOD TRANSFUSION, 2019, 17 (03) : 223 - 228
  • [10] Emicizumab for acquired haemophilia A: A case series
    Engelen, Matthias M.
    Vandesande, Johan
    De Bent, Johan
    Van Laer, Christine
    Labarque, Veerle
    Jacquemin, Marc
    Peerlinck, Kathelijne
    Hermans, Cedric
    Verhamme, Peter
    Vanassche, Thomas
    [J]. HAEMOPHILIA, 2023, 29 (04) : 1049 - 1055
12345